Intra-articular enzyme replacement therapy with rhIDUA is safe, well-tolerated, and reduces articular GAG storage in the canine model of mucopolysaccharidosis type I

This publication has 29 references indexed in Scilit:

• Acid Ceramidase Maintains the Chondrogenic Phenotype of Expanded Primary Chondrocytes and Improves the Chondrogenic Differentiation of Bone Marrow-Derived Mesenchymal Stem Cells
  PLOS ONE, 2013
• Involvement of the Toll-like receptor 4 pathway and use of TNF-α antagonists for treatment of the mucopolysaccharidoses
  Proceedings of the National Academy of Sciences, 2009
• Mechanism of shortened bones in mucopolysaccharidosis VII
  Molecular Genetics and Metabolism, 2009
• Evolutionary Differences in Glycosaminoglycan Fine Structure Detected by Quantitative Glycan Reductive Isotope Labeling
  Journal of Biological Chemistry, 2008
• Immune tolerance improves the efficacy of enzyme replacement therapy in canine mucopolysaccharidosis I
  Journal of Clinical Investigation, 2008
• Early Neurodegeneration Progresses Independently of Microglial Activation by Heparan Sulfate in the Brain of Mucopolysaccharidosis IIIB Mice
  PLOS ONE, 2008
• Immune tolerance after long-term enzyme-replacement therapy among patients who have mucopolysaccharidosis I
  The Lancet, 2003
• Enzyme Replacement Therapy in Feline Mucopolysaccharidosis I
  Molecular Genetics and Metabolism, 2001
• Long-Term and High-Dose Trials of Enzyme Replacement Therapy in the Canine Model of Mucopolysaccharidosis I
  Biochemical and Molecular Medicine, 1996
• Architecture of the canine IDUA gene and mutation underlying canine mucopolysaccharidosis I
  Genomics, 1992